Effect of Growth Hormone Treatment on Diastolic Function in Patients Who Have Developed Growth Hormone Deficiency After Definitive Treatment of Acromegaly

Overview

Journal Growth Horm IGF Res

Publisher Elsevier

Specialty Endocrinology

Date 2016 Jan 18

PMID 26774401

Citations 2

Authors

Pouneh K Fazeli

Jonathan G Teoh

Eleanor L Lam

Anu V Gerweck

Tamara L Wexler

Eliza P Teo

Brian M Russell

Ronen Durst

David McCarty

Rory B Weiner

Michael H Picard

Anne Klibanski

Karen K Miller

Affiliations

Soon will be listed here.

Abstract

Objective: Although growth hormone (GH) replacement is prescribed for patients with hypopituitarism due to many etiologies, it is not routinely prescribed for patients with GH deficiency (GHD) after cure of acromegaly (acroGHD). This study was designed to investigate the effect of GH replacement on cardiac parameters in acroGHD.

Design: We prospectively evaluated for 12months 23 patients with acroGHD: 15 subjects on GH replacement and eight subjects not on GH replacement. Main outcome measures included LV mass corrected for body surface area (LVM/BSA) and measures of diastolic dysfunction (E/A ratio and deceleration time), as assessed by echocardiography.

Results: After 12months of follow-up, there were no differences between the GH-treated group and the untreated group in LVM/BSA (GH: 74.4±22.5g/m(2) vs untreated: 72.9±21.3g/m(2), p=0.89), E/A ratio (GH: 1.21±0.39 vs untreated: 1.08±0.39, p=0.50) or deceleration time (GH: 224.5±60.1ms vs untreated: 260±79.8ms, p=0.32). The overall degree of diastolic function was similar between the groups with 42.9% of untreated subjects and 50% of GH-treated subjects (p=0.76) classified as having normal diastolic function at follow-up.

Conclusions: There were no significant differences in LVM/BSA or parameters of diastolic function in patients with a history of acromegaly treated for GHD as compared to those who were untreated. These data are reassuring with respect to cardiovascular safety with GH use after treatment for acromegaly, although further longer term study is necessary to evaluate the safety and efficacy of GH treatment in this population.

Citing Articles

Filling the gap between the heart and the body in acromegaly: a case-control study.

Sagova I, Dragula M, Mokan M, Vanuga P Endocrine. 2022; 79(2):365-375.

PMID: 36309947 PMC: 9892104. DOI: 10.1007/s12020-022-03232-3.

Heart in Acromegaly: The Echocardiographic Characteristics of Patients Diagnosed with Acromegaly in Various Stages of the Disease.

Popielarz-Grygalewicz A, Gasior J, Konwicka A, Grygalewicz P, Stelmachowska-Banas M, Zgliczynski W Int J Endocrinol. 2018; 2018:6935054.

PMID: 30123265 PMC: 6079421. DOI: 10.1155/2018/6935054.

References

Frustaci A, Chimenti C, Setoguchi M, Guerra S, Corsello S, Crea F . Cell death in acromegalic cardiomyopathy. Circulation. 1999; 99(11):1426-34. DOI: 10.1161/01.cir.99.11.1426. View

Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W . The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab. 2004; 89(12):5998-6004. DOI: 10.1210/jc.2004-1042. View

Vilar L, Naves L, Costa S, Abdalla L, Coelho C, Casulari L . Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract. 2007; 13(4):363-72. DOI: 10.4158/EP.13.4.363. View

De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A . The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary. 2007; 11(1):13-20. DOI: 10.1007/s11102-007-0062-6. View

Beauregard C, Utz A, Schaub A, Nachtigall L, Biller B, Miller K . Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008; 93(6):2063-71. PMC: 2435650. DOI: 10.1210/jc.2007-2371. View

Norrman L, Johannsson G, Sunnerhagen K, Svensson J . Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab. 2008; 93(7):2531-8. DOI: 10.1210/jc.2007-2673. View

Delaroudis S, Efstathiadou Z, Koukoulis G, Kita M, Farmakiotis D, Dara O . Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf). 2008; 69(2):279-84. DOI: 10.1111/j.1365-2265.2008.03181.x. View

Nagueh S, Appleton C, Gillebert T, Marino P, Oh J, Smiseth O . Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009; 22(2):107-33. DOI: 10.1016/j.echo.2008.11.023. View

Ronchi C, Giavoli C, Ferrante E, Verrua E, Bergamaschi S, Ferrari D . Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments. Eur J Endocrinol. 2009; 161(1):37-42. DOI: 10.1530/EJE-09-0222. View

10.

Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G . Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab. 2009; 94(7):2471-7. PMC: 2708960. DOI: 10.1210/jc.2008-2671. View

11.

Colao A, Auriemma R, Galdiero M, Lombardi G, Pivonello R . Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009; 94(10):3746-56. DOI: 10.1210/jc.2009-0941. View

12.

van der Klaauw A, Bax J, Roelfsema F, Stokkel M, Bleeker G, Biermasz N . Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary. 2009; 12(4):339-46. PMC: 2764055. DOI: 10.1007/s11102-009-0186-y. View

13.

Miller K, Wexler T, Fazeli P, Gunnell L, Graham G, Beauregard C . Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab. 2010; 95(2):567-77. PMC: 2840863. DOI: 10.1210/jc.2009-1611. View

14.

Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, Pinkney J . The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res. 2010; 20(3):220-5. DOI: 10.1016/j.ghir.2010.02.002. View

15.

Wexler T, Durst R, McCarty D, Picard M, Gunnell L, Omer Z . Growth hormone status predicts left ventricular mass in patients after cure of acromegaly. Growth Horm IGF Res. 2010; 20(5):333-7. PMC: 3670701. DOI: 10.1016/j.ghir.2010.05.003. View

16.

van Bunderen C, van Nieuwpoort I, Arwert L, Heymans M, Franken A, Koppeschaar H . Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab. 2011; 96(10):3151-9. DOI: 10.1210/jc.2011-1215. View

17.

Hazem A, Elamin M, Bancos I, Malaga G, Prutsky G, Domecq J . Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2011; 166(1):13-20. DOI: 10.1530/EJE-11-0558. View

18.

Lin E, Wexler T, Nachtigall L, Tritos N, Swearingen B, Hemphill L . Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clin Endocrinol (Oxf). 2012; 77(3):430-8. PMC: 3366162. DOI: 10.1111/j.1365-2265.2012.04361.x. View

19.

Giavoli C, Profka E, Verrua E, Ronchi C, Ferrante E, Bergamaschi S . GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. J Clin Endocrinol Metab. 2012; 97(11):3983-8. DOI: 10.1210/jc.2012-2477. View

20.

Tritos N, Johannsson G, Korbonits M, Miller K, Feldt-Rasmussen U, Yuen K . Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis. J Clin Endocrinol Metab. 2014; 99(6):2018-29. DOI: 10.1210/jc.2014-1013. View